Medication info
Linagliptin Metformin Duo Tablet 2.5/1000 mg

Linagliptin Metformin Duo Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Bright pink, bilaterally convex, oval-shaped film-coated tablet
Packaging
10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box[(10 tablets/PTP×3)]
Approval status
Active

MFDS item code 201902755 · Approved 2019.04.29 · Insurance code 642906840

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to decrease the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, the insulin dose may need to be reduced to decrease the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antidiabetic drugs to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that could increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes control their blood sugar more effectively when combined with dietary changes and exercise. Linagliptin and metformin are used in combination to stabilize blood glucose levels. Thus, this medication plays a significant role in diabetes treatment and helps improve blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, the sulfonylurea dose may need to be reduced to decrease the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, the insulin dose may need to be reduced to decrease the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antidiabetic drugs to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other symptoms that could increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Precautions

This medication is designed to help regulate blood sugar levels. However, a rare side effect called lactic acidosis can occur during treatment, which is a serious condition requiring immediate treatment. This medication should not be used in patients with certain conditions, such as type 1 diabetes, severe kidney impairment, liver dysfunction, acute heart issues, acute infections, or pregnant women. Additionally, since this medication can cause hypoglycemia, caution is needed when taken with insulin or sulfonylureas, and dosage adjustments may be necessary. Patients with reduced kidney function should undergo regular kidney function tests, and if kidney function falls below a certain standard, this medication should be discontinued. It should be temporarily stopped before and after surgery or radiological examinations, and can be resumed once kidney function has recovered post-surgery. If sudden abdominal pain, severe joint pain, or symptoms such as blistering on the skin occur during treatment, consult a doctor immediately. Long-term use may decrease vitamin B12 levels, so monitoring through blood tests may be necessary if needed. This medication can interact with several other drugs, so be sure to inform your doctor or pharmacist if you are taking other medications. It is advisable for pregnant or breastfeeding women not to use this medication and is not recommended for children or adolescents. Elderly patients may commonly experience decreased kidney function, so careful dosage adjustments and regular kidney function checks are necessary. In the event of overdose, there is a risk of gastrointestinal disturbances or lactic acidosis, requiring immediate hospital treatment, and blood dialysis may be necessary. Store this medication in a closed container, keeping it away from moisture and direct sunlight, and out of reach of children.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 125 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • oral ulcers
  • hepatitis
  • rash
  • pruritus
  • erythema
  • severe joint pain
  • bullous pemphigoid
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech impairment
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • concussion
  • contusion
  • bone contusion
  • meniscus injury
  • foot fracture
  • hand fracture
  • pneumoconiosis
  • laceration
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • acute kidney injury
  • polyuria
  • proteinuria
  • end-stage renal disease
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hearing loss
  • dizziness
  • erectile dysfunction
  • thyroid goiter
  • kidney transplant failure
  • anemia
  • vertigo
  • sensory impairment
  • headache
  • drowsiness
  • chest discomfort
  • weakness
  • nosebleed
  • oropharyngeal pain
  • voice disorders
  • nasal bleeding
  • vocal cord polyp
  • hypertension
  • itching
  • insomnia
  • depression
  • anxiety
  • confusion
  • nocturia
  • dermatitis
  • osteoarthritis
  • limb pain
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • rotator cuff syndrome
  • benign prostatic hyperplasia
  • myelodysplastic syndrome
  • papilloma
  • thyroid nodule
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it should be kept in a place that is not too hot or cold, ideally at a room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Bright pink, bilaterally convex, oval-shaped film-coated tablet

Package unit

10 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle, 30 tablets/box[(10 tablets/PTP×3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.